PROTOCOL THS 94-002 
REVISED Q5l2hl9i* 
PAGE 4 of 6 
designated associates to administer the treatment. 
8. I have been told and understand that my participation in this clinical 
research study is voluntary. I may decide not to participate, or withdraw' 
my consent and discontinue my participation at any time. Such action will 
be without prejudice and there shall be no penalty or loss of benefits to 
which I may otherwise be entitled, and I will continue to receive treatment 
by my physician at this institution. 
Should I decide not to participate or withdraw my consent from participation 
in this clinical research, I have been advised that I should discuss the 
consequences or effects of my decision with my physician. 
In addition, I understand that the investigator may discontinue the clinical 
research study if, in the sole opinion and discretion of the investigator, the 
study or treatment offers me little or no future benefit, or the supply of 
medication ceases to be available or other causes prevent continuation of 
the clinical research study. The investigator will notify me should such 
circumstances arise and my physician will advise me about available 
treatments which may be of benefit at that time. 
I will be informed of any new findings developed during the course of this 
clinical research study which might be relevant to my willingness to 
continue participation In the study. 
9. I have been assured that confidentiality will be preserved except that 
qualified monitors from the Food and Drug Administration, Microbiological 
Associates, Magenta Corporation (manufacturers of the virus), and National 
Cancer Institute may review my records where appropriate and necessary. 
Qualified monitors shall include assignees authorized by the Surveillance 
Committee of this institution provided that confidentiality is assured and 
preserved. My name will not be revealed in any reports or publications 
resulting from this study, without my expressed consent. 
10. I have been informed that, should I suffer any injury as a result of 
participation in this research activity, reasonable medical facilities are 
available for treatment at this institution. I understand, however, that I 
cannot expect to receive any credit or reimbursement for expenses from this 
institution or any financial compensation from this institution for such injury. 
11. I have been informed that I should Inquire of the attending physician 
whether or not there are any services, investigational agents or devices, 
and/or medications being offered by the sponsor of this clinical research 
project at a reduced cost or without cost. Should the investigational agent 
become commercially available during the course of the study, I understand 
that I may be required to cover the cost of subsequent doses. 
Recombinant DNA Research, Volume 19 
[607] 
